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Recurrent histone mutations in T-cell acute lymphoblastic
leukaemia
Mutations affecting key modifiable histone type 3 (H3;
Table SI) residues are frequent oncogenic events in certain
solid tumours (Feinberg et al, 2016), and have also recently
been implicated in a subset of acute myeloid leukaemia
(AML) (Lehnertz et al, 2017). Here, we systematically
reviewed the somatic mutations in >20 000 cancer specimens
to identify tumours harbouring H3 mutations. In a subset of
T-cell acute lymphoblastic leukaemia (T-ALL) we identified
non-methionine mutations of the key modifiable H3 resi-
dues, lysine (K) 27 and 36.
The starting point of our investigation was a search for H3
hotspot mutations in 1020 human cancer cell lines (Table SII).
In two cell lines, both derived from T-ALL, we found lysine-
to-arginine mutations at H3K27 and H3K36 (Table I). One of
the cell lines, LOUCY, is derived from a NOTCH1 wild-type
adult T-ALL (Ben-Bassat et al, 1990). The second, CML-T1,
was derived from the T-lymphoblastic blast crisis of chronic
myeloid leukaemia (Kuriyama et al, 1989). Ten further T-ALL
cell lines lacked coding H3 mutations (Table SIII). In solid
tumours, H3K27 and H3K36 are typically mutated to
methionine (Fig 1) (Feinberg et al, 2016). However, recent
functional studies of H3 lysine-to-isoleucine mutations in
AML demonstrate that the latter also dramatically alter global
H3 methylation and acetylation patterns (Lehnertz et al,
2017). Therefore, we speculated that lysine-to-non-methionine
mutations may also be drivers of a subset of T-ALL.
We next searched for canonical H3 mutations in a pub-
lished targeted sequencing study of 633 epigenetic regulator
genes in >1000 childhood tumours encompassing 21 cancer
subtypes (Huether et al, 2014). Amongst 91 T-ALL speci-
mens, there were two cases with canonical H3 mutations:
H3F3A p.K27R and H3F3A p.K36R (Table I). Both muta-
tions were clonal, with a variant allele fraction (VAF) of 38%
and 55%, respectively. Among the 37 tumours with H3K
mutations, lysine-to-arginine mutations were restricted to T-
ALL (P = 0001502; Fisher’s exact test).
We then extended our screen for H3 mutations to 18 704
tumours, encompassing >60 cancer types other than T-ALL
(Tables SIV and SV). This dataset comprised 8764 internally
sequenced specimens and 9940 TCGA samples re-analysed
using an in-house variant calling pipeline as previously
described (Martincorena et al, 2017). We identified only one
neomorphic H3 mutation in an acute leukaemia specimen: a
previously reported HIST1H3D p.K27M mutation in an adult
AML case (TCGA-AB2927-03) (Lehnertz et al, 2017).
Finally, we examined an additional T-ALL cohort by capil-
lary sequencing of recurrently mutated modifiable residues
K27, G34, and K36 across four frequently mutated H3 genes
(Tables SVI and SVII). The cohort comprised 38 T-ALL cases
described in detail previously (Maser et al, 2007). One speci-
men from a 30-year-old patient harboured a H3F3A p.K27N
mutation (Figure S1). Interestingly, a H3F3A p.K27N muta-
tion and a H3F3A p.K27T variant were previously identified
in a T-ALL RNA sequencing study (n = 31) (Atak et al,
2013). Collectively, our findings indicate that H3K27 and
H3K36 mutations are recurrent in T-ALL, a result we were
able to reproduce across multiple different cohorts encom-
passing adult and paediatric cases.
This finding is congruent with the fact that mutations in
SETD2 and EZH2, methyltransferases that catalyse trimethyla-
tion (me3) of H3K36 and H3K27, respectively, are frequent
T-ALL drivers (Belver & Ferrando, 2016). Disruptive SETD2
alterations occur in 78% of early T cell precursor acute lym-
phoblastic leukaemia (ETP-ALL), an aggressive subtype with
stem cell-like features (Belver & Ferrando, 2016). Interestingly,
both T-ALL specimens with H3K36R mutations originated
from ETP-ALL (Table I). Notably, mutually exclusive SETD2
and H3K36/H3K34 mutations are reported in paediatric high
grade glioma, where both result in reduced H3K36me3 medi-
ated by SETD2 (Feinberg et al, 2016). It is unclear whether a
similar co-mutation pattern exists in T-ALL, as H3 genes have
not been included in targeted sequencing panels used by the
largest T-ALL genomic studies (Belver & Ferrando, 2016).
The role of H3K27 modifications in T-ALL pathogenesis is
complex (Belver & Ferrando, 2016). It is plausible that muta-
tions affecting this residue could impact the activity of sev-
eral histone modifiers with established roles in T-ALL
pathogenesis. Loss-of-function mutations in EZH2 or other
core components of Polycomb repressive complex 2 (PRC2)
are found in 42% of ETP-ALL and 25% of T-ALL overall
(Belver & Ferrando, 2016). Impaired PRC2 catalytic activity
in T-ALL is associated with reduced H3K27me3, stemness
and poor prognosis (Belver & Ferrando, 2016). H3F3A
p.K27M mutations appear to act predominantly by blocking
H3K27 di- and trimethylation and increasing H3K27 acetyla-
tion (Feinberg et al, 2016). Recent work demonstrates that
H3K27I mutations in AML are associated with similar
changes in H3 modification patterns (Lehnertz et al, 2017),
suggesting that other non-methionine mutations at modifi-
able H3 residues may influence the activity of PRC2 and
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other histone modifying enzymes. The lysine-specific
demethylases JMJD3 and UTX are further important regula-
tors of H3K27me3 distribution in T-ALL (Belver & Ferrando,
2016), and it is conceivable that these enzymes may also be
affected by H3K27 or H3K36 mutations.
A feature of H3 mutations in solid cancers is their exqui-
site tumour type specificity (Fig 1) (Feinberg et al, 2016). In
this context, it is notable that 5/5 H3 mutations in T-ALL
identified by this survey are lysine-to-non-methionine muta-
tions, and 4/5 are lysine-to-arginine mutations. Out of the
>20 000 tumour specimens screened for H3 variants, only
two other samples harboured H3 lysine-to-arginine muta-
tions, both at low VAF and in tumours with relatively high
coding mutation burdens (TCGA-BT-A20Q-01 and TCGA-
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Fig 1. Prevalence and amino acid specificity of type 3 histone mutations in different cancer types. Columns indicate cancer types and rows show
key histone type 3 regulatory residues. Tiles are coloured according to amino acid substitution. The percentage of each tumour type affected by
the given class of histone mutation is indicated within the tiles and the overall prevalence of histone mutations is summarised at the bottom of
each column. NBS HGG, non-brain stem high grade glioma; DIPG, diffuse intrinsic pontine glioma; ASTR, astrocytoma; AML, acute myeloid
leukaemia; T-ALL, T cell acute lymphoblastic leukaemia; OS, osteosarcoma; ADM, adamantinoma; GCTB, giant cell tumour of bone; CCC, clear
cell chondrosarcoma; CB, chondroblastoma; CS, chondrosarcoma.
Table I. Type 3 histone mutations in T cell leukaemia.
Sample name Sample type Donor age (years) Donor sex H3 mutation
LOUCY Cell line derived from ETP-ALL 38 Female HIST1H3G p.K36R
CML-T1 Cell line derived from the acute T-lympoblastic
blast crisis of CML
36 Female H3F3A p.K27R
SJTALL174 Primary ETP-ALL specimen Unknown (paediatric) Unknown H3F3A p.K36R
SJTALL080 Primary T-ALL specimen Unknown (paediatric) Unknown H3F3A p.K27R
PD2752a Primary T-ALL specimen 30 Male H3F3A p.K27N
Out of 141 T cell leukaemia specimens screened (12 cell lines and 129 primary samples), 5 (35%) harboured a missense mutation at a modifiable
lysine residues K27 or K36. CML, chronic myeloid leukaemia; ETP-ALL, early T cell precursor acute lymphoblastic leukaemia; T-ALL, T cell acute
lymphoblastic leukaemia.
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AN-A0FW-01). Hence, it is possible that lysine-to-arginine
mutations confer particular selective advantage in the context
of T cell leukaemogenesis.
In summary, ~3% of T-ALL harbour non-methionine vari-
ants in H3 genes at key modifiable lysine residues. Given the
role of dysregulated H3K27/H3K36 modification in T-ALL
pathogenesis and the established prognostic significance of
mutations in lysine-specific histone modifiers (Belver & Fer-
rando, 2016), this finding warrants further investigation of the
prevalence, clinical and functional significance of H3 muta-
tions in T-ALL. In light of the recent discovery of oncogenic
H3K37 mutations in AML (Lehnertz et al, 2017), our findings
suggest a broader role for histone mutations in acute leukae-
mias and clearly justify incorporation of H3 genes into haema-
tological cancer sequencing panels.
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